ARCHIVES

Most of NCI’s $60 Million Increase In FY95 will fund Mandatory Raise In Prevention

This article is from The Cancer Letter archive.

Vol. 20 No. 39 | October 14, 1994

Download PDF Visit The Full Archive

Related Articles

Bristol-Myers, IVAX submit Competing Application for Paclitaxel Use In KS

April 18, 1997

DCPC Board Okays Reissuance Of RFA for Chemoprevention Clinical Trials

May 20, 1988

FDA Grants Accelerated Approval to Imbruvica

November 29, 2013

Phase II Study: Proton Therapy Can Have Similar Success Rate, Smaller Level of Risk in Treatment of Hodgkin Lymphoma

July 25, 2014

New NCAB Weak In Grant Reviews, Confused By Issues

December 10, 1982

In Brief: Lawsuit Developing Over NCI X-Ray Contract; Califano May attempt To Trim NCI Authority

August 19, 1977